Here, we present the clinical data from the Taiwan EAP on the real-world effectiveness of osimertinib administration in patients with EGFR T790M-positive locally advanced or metastatic NSCLC following progression on at least one prior EGFR-TKI treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.